Edwards Lifesciences’ Second‐Quarter Momentum Extended by Anticipated Medicare Coverage Decision and Regulatory Outlook

Edwards Lifesciences (NYSE: EW) further solidified its growth trajectory this week as attention turns to a pivotal Medicare coverage decision that could markedly expand access to its TAVR technology.

Expected Medicare Approval Could Unlock Broader Access

The Centers for Medicare & Medicaid Services (CMS) is progressing with its reconsideration of the National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR), with a final decision memo expected to be released in September. This development, emerging after the company’s July 23 earnings release, represents a potential turning point for accessibility of the procedure among Medicare beneficiaries. If favorable, it could significantly expand Edwards’ addressable market. Edwards highlighted this pending decision in its Q2 report. (reported Jul. 23, event pending)

Strong Fiscal Second Quarter Performance

On July 23, Edwards reported second-quarter results for the period ended June 30, 2026, with total sales reaching $1.74 billion, a 13.6% year-over-year increase (12.5% on a constant currency basis). TAVR sales alone rose 11.3% to approximately $1.26 billion (10.5% constant currency). Adjusted EPS came in at $0.78, ahead of expectations, while the company raised its full-year guidance for both total and TAVR sales. These results underscore robust product demand and operational strength. (reported Jul. 23)

Strategic Catalysts in Product Pipeline and Evidence Generation

The recent New York Valves conference further bolstered investor confidence, showcasing strong long-term data for Edwards’ SAPIEN valve—including a 7‑year PARTNER 3 sub-analysis and 5‑year EARLY TAVR results—and reinforcing its positioning. Edwards also reaffirmed expectations for U.S. regulatory approvals in Q4 for PASCAL’s tricuspid indication and its next-generation PASCAL with Capture Clarity. Additionally, the EVOQUE and SAPIEN M3 systems continue to scale, supported by growing clinical data and procedural adoption. (reported Jul. 23)

Stock Performance and Broader Market Sentiment

As of September 10, 2026, Edwards’ stock is trading at $86.77, reflecting a 0.9% daily gain. While this movement comes after the Q2 results, there is no specific reporting tying the uptick directly to the Medicare decision—but the company’s strategic positioning may underlie investor optimism. (live price)

Why It Matters to Investors

The upcoming CMS decision stands out as a material inflection point that could reshuffle the competitive landscape for structural heart procedures in the U.S. A favorable outcome could meaningfully expand TAVR adoption among a broader patient base. Coupled with the demonstrated strength of Edwards’ portfolio—anchored by SAPIEN, PASCAL, EVOQUE, and SAPIEN M3—this positions the company to sustain long-term growth.

Investors should closely monitor the CMS memo expected in September. A positive ruling could significantly enhance Edwards Lifesciences’ market opportunity, validating its elevated guidance and reinforcing its leadership in structural heart innovations.